Pub Date : 2022-07-20DOI: 10.17650/1818-8346-2022-17-3-114-118
L. S. Khayrullina, M. A. Vernyuk, A. Chervontseva, I. Cherkashina, E. E. Gushchina, A. Fedenko
Classical Hodgkin's lymphoma is one of the most treatable lymphoproliferative diseases with current chemotherapy regimens. The 5-year overall survival rate among patients after initial chemotherapy reaches 95 %, however, despite the significant success achieved, the problem of refractoriness/relapse remains very relevant. A standard approach to the treatment of refractory/recurrent Hodgkin's lymphoma among young patients with preserved general status and chemoresponsive to salvage therapy tumor is high-dose consolidation chemotherapy followed by transplantation of autologous hematopoietic stem cells. The intensification of chemotherapy regimens is highly difficult task for a doctor during the COVID-19 pandemic, which requires careful assessment of a risk-benefit ratio.In current conditions, new targeted and immune drugs are used to overcome resistance and reduce toxicity among pretreated patients, which allows not only to improve the results of a treatment, but also to preserve the high quality of life among patients with extremely unfavorable prognosis.We show our experience of using a checkpoint inhibitor in combination with a dose-intensive regimen of DHAP (dexamethasone, cytarabine, cisplatin) in the treatment of a refractory classical Hodgkin's lymphoma followed by high-dose consolidation chemotherapy and allogeneic hematopoietic stem cells transplantation, among patients complicated with a new coronavirus infection in the post-transplant period.
{"title":"Immunochemotherapy of refractory classical Hodgkin's lymphoma with high-dose consolidation and autologous hematopoietic stem cell transplantation complicated by a new coronavirus infection","authors":"L. S. Khayrullina, M. A. Vernyuk, A. Chervontseva, I. Cherkashina, E. E. Gushchina, A. Fedenko","doi":"10.17650/1818-8346-2022-17-3-114-118","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-3-114-118","url":null,"abstract":"Classical Hodgkin's lymphoma is one of the most treatable lymphoproliferative diseases with current chemotherapy regimens. The 5-year overall survival rate among patients after initial chemotherapy reaches 95 %, however, despite the significant success achieved, the problem of refractoriness/relapse remains very relevant. A standard approach to the treatment of refractory/recurrent Hodgkin's lymphoma among young patients with preserved general status and chemoresponsive to salvage therapy tumor is high-dose consolidation chemotherapy followed by transplantation of autologous hematopoietic stem cells. The intensification of chemotherapy regimens is highly difficult task for a doctor during the COVID-19 pandemic, which requires careful assessment of a risk-benefit ratio.In current conditions, new targeted and immune drugs are used to overcome resistance and reduce toxicity among pretreated patients, which allows not only to improve the results of a treatment, but also to preserve the high quality of life among patients with extremely unfavorable prognosis.We show our experience of using a checkpoint inhibitor in combination with a dose-intensive regimen of DHAP (dexamethasone, cytarabine, cisplatin) in the treatment of a refractory classical Hodgkin's lymphoma followed by high-dose consolidation chemotherapy and allogeneic hematopoietic stem cells transplantation, among patients complicated with a new coronavirus infection in the post-transplant period.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89498899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-19DOI: 10.17650/1818-8346-2022-17-3-40-47
A. Mamedova, N. Mochkin, V. Sarzhevskiy, E. Demina, V. Bogatyrev, A. Spornik, A. Samoylova, A. Rukavitsin, E. Smirnova, A. Bannikova, V. Melnichenko, N. Mikhaylova, E. Borzenkova, L. Stelmakh, Y. Zalyalov, A. A. Semenova, G. Tumyan, M. Danilova, O. Konova, N. Falaleeva, A. Terekhova, M. A. Vernyuk, A. Chervontseva, L. S. Khayrullina, A. Maslov, I. Lysenko, Yuliya Alekseeva, E. S. Pavlyuchenko, A. A. Mirsaitov, A. Zverkova, I. Ishmatova, S. Volchenkov, M. Motalkina, I. Zyuzgin
Aim. To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.Materials and methods. The study consisted of 2 phases: 1st - immunotherapy with nivolumab (2 injections as monotherapy at a dose of 240 mg/day with 14 days interval); 2nd - combined immunochemotherapy according to the DHAp protocol + nivolumab (14 days after the 2nd administration of nivolumab): nivolumab 480 mg/day on day 1 in combination with chemotherapy according to the DHAp protocol, 4 cycles in total. The effectiveness of therapy was evaluated after 2 injections of nivolumab, after 2 and 4 cycles of combination therapy. from March 2020 to November 2021, 32 patients were included in the study. The median age was 34 (18-55) years.Results. As of November 2021, the result was evaluated in 32 patients after the 1st stage of treatment (nivolumab monotherapy). A complete response was obtained in 4 (12.5 %) patients, a partial response in 20 (62.5 %) patients, disease stabilization was noted in 5 (16 %) patients, an indeterminate response in 3 (9 %) patients. At the 2nd phase, the efficacy after the 2nd cycle of DHAp + nivolumab was evaluated in 31 patients (complete response was obtained in 19 (61 %), partial response in 11 (36 %)); the final efficacy evaluation (after the 4th cycle of DHAp + nivolumab) was performed in 30 patients, and all patients achieved response to therapy (complete response in 25 (83 %), partial response in 5 (17 %)). 2 patients were excluded from the study.Conclusion. preliminary results of combined immuno- and chemotherapy according to the DHAp protocol showed high efficacy and relatively low toxicity in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.
{"title":"Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2nd line treatment before autologous hematopoietic stem cell transplantation (preliminary results)","authors":"A. Mamedova, N. Mochkin, V. Sarzhevskiy, E. Demina, V. Bogatyrev, A. Spornik, A. Samoylova, A. Rukavitsin, E. Smirnova, A. Bannikova, V. Melnichenko, N. Mikhaylova, E. Borzenkova, L. Stelmakh, Y. Zalyalov, A. A. Semenova, G. Tumyan, M. Danilova, O. Konova, N. Falaleeva, A. Terekhova, M. A. Vernyuk, A. Chervontseva, L. S. Khayrullina, A. Maslov, I. Lysenko, Yuliya Alekseeva, E. S. Pavlyuchenko, A. A. Mirsaitov, A. Zverkova, I. Ishmatova, S. Volchenkov, M. Motalkina, I. Zyuzgin","doi":"10.17650/1818-8346-2022-17-3-40-47","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-3-40-47","url":null,"abstract":"Aim. To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.Materials and methods. The study consisted of 2 phases: 1st - immunotherapy with nivolumab (2 injections as monotherapy at a dose of 240 mg/day with 14 days interval); 2nd - combined immunochemotherapy according to the DHAp protocol + nivolumab (14 days after the 2nd administration of nivolumab): nivolumab 480 mg/day on day 1 in combination with chemotherapy according to the DHAp protocol, 4 cycles in total. The effectiveness of therapy was evaluated after 2 injections of nivolumab, after 2 and 4 cycles of combination therapy. from March 2020 to November 2021, 32 patients were included in the study. The median age was 34 (18-55) years.Results. As of November 2021, the result was evaluated in 32 patients after the 1st stage of treatment (nivolumab monotherapy). A complete response was obtained in 4 (12.5 %) patients, a partial response in 20 (62.5 %) patients, disease stabilization was noted in 5 (16 %) patients, an indeterminate response in 3 (9 %) patients. At the 2nd phase, the efficacy after the 2nd cycle of DHAp + nivolumab was evaluated in 31 patients (complete response was obtained in 19 (61 %), partial response in 11 (36 %)); the final efficacy evaluation (after the 4th cycle of DHAp + nivolumab) was performed in 30 patients, and all patients achieved response to therapy (complete response in 25 (83 %), partial response in 5 (17 %)). 2 patients were excluded from the study.Conclusion. preliminary results of combined immuno- and chemotherapy according to the DHAp protocol showed high efficacy and relatively low toxicity in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72726076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-19DOI: 10.17650/1818-8346-2022-17-3-24-30
Yu. E. Ryabukhina, F. М. Abbasbeyli, P. A. Zeynalova, O. L. Timofeeva, A. Batsev, G. Allakhverdieva, O. Sinitsina, A. G. Zhukov
Follicular lymphoma is a tumor of mature B-lymphocytes, characterized by a predominantly indolent course. Despite advances in first-line therapy, disease relapses still occur, and with an increase in the follow-up period, the risk of transformation into diffuse large B-cell lymphoma also increases. The choice of a further anticancer therapy is based on the results of a comprehensive examination and repeated biopsy. In addition, previous remission duration, previous treatment, clinical manifestation of relapse, the patient's somatic condition and comorbidity are taken into account. A clinical observation of a 57-year-old patient with relapsed follicular lymphoma, who received various chemotherapy regimens in combination with rituximab in the 1st and subsequent lines, is presented. After repeated biopsy and exclusion of transformation into diffuse large B-cell lymphoma, the patient received lenalidomide therapy in combination with obinutuzumab. A partial antitumor response after 4 cycles with decrease in tumor volume by more than 80 % by the end of induction was achieved. The absence of severe adverse events, together with a pronounced antitumor effect, significantly improved the patient's quality of life.
{"title":"Modern approaches to the treatment of relapsed follicular lymphoma","authors":"Yu. E. Ryabukhina, F. М. Abbasbeyli, P. A. Zeynalova, O. L. Timofeeva, A. Batsev, G. Allakhverdieva, O. Sinitsina, A. G. Zhukov","doi":"10.17650/1818-8346-2022-17-3-24-30","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-3-24-30","url":null,"abstract":"Follicular lymphoma is a tumor of mature B-lymphocytes, characterized by a predominantly indolent course. Despite advances in first-line therapy, disease relapses still occur, and with an increase in the follow-up period, the risk of transformation into diffuse large B-cell lymphoma also increases. The choice of a further anticancer therapy is based on the results of a comprehensive examination and repeated biopsy. In addition, previous remission duration, previous treatment, clinical manifestation of relapse, the patient's somatic condition and comorbidity are taken into account. A clinical observation of a 57-year-old patient with relapsed follicular lymphoma, who received various chemotherapy regimens in combination with rituximab in the 1st and subsequent lines, is presented. After repeated biopsy and exclusion of transformation into diffuse large B-cell lymphoma, the patient received lenalidomide therapy in combination with obinutuzumab. A partial antitumor response after 4 cycles with decrease in tumor volume by more than 80 % by the end of induction was achieved. The absence of severe adverse events, together with a pronounced antitumor effect, significantly improved the patient's quality of life.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72521865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-19DOI: 10.17650/1818-8346-2022-17-3-31-39
Yu. A. Nikulin
Прошедший в Москве VI конгресс гематологов России (традиционно с международным участием) собрал, как и ранее, ведущих представителей одного из наиболее обширных и сложных медицинских направлений. Несмотря на то что ряд зарубежных специалистов выступили дистанционно, это не уменьшило ни содержательности обсуждаемых тем, ни интереса к ним.
{"title":"According to the materials of the VI Congress of Hematologists of Russia and the III Congress of Transfusiologists of Russia. Immunotherapy for multiple myeloma: from first drugs to overcoming resistance","authors":"Yu. A. Nikulin","doi":"10.17650/1818-8346-2022-17-3-31-39","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-3-31-39","url":null,"abstract":"Прошедший в Москве VI конгресс гематологов России (традиционно с международным участием) собрал, как и ранее, ведущих представителей одного из наиболее обширных и сложных медицинских направлений. Несмотря на то что ряд зарубежных специалистов выступили дистанционно, это не уменьшило ни содержательности обсуждаемых тем, ни интереса к ним.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"2020 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75573269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-18DOI: 10.17650/1818-8346-2022-17-3-14-23
Y. Ryabukhina
В Онкологическом центре Клинического госпиталя «Лапино» группы компаний «Мать и дитя» 10 сентября 2021 г. состоялась конференция, посвященная тактике ведения пациентов с онкогематологическими заболевани ями в ургентных клинических ситуациях.На конференции с докладами выступили не только ведущие российские онкологи и гематологи, но и врачи других специальностей (по поддерживающей терапии, инструментальной диагностике, анестезиологи-реаниматологи, акушеры-гинекологи, патоморфологи).Были освещены самые актуальные вопросы диагностики и лечения пациентов в тех случаях, когда незамедлительная правильно выбранная тактика может способствовать благоприятному прогнозу.
{"title":"According to the materials of the Conference “Algorithms of emergency situations in oncohematology. Approaches and treatment”","authors":"Y. Ryabukhina","doi":"10.17650/1818-8346-2022-17-3-14-23","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-3-14-23","url":null,"abstract":"В Онкологическом центре Клинического госпиталя «Лапино» группы компаний «Мать и дитя» 10 сентября 2021 г. состоялась конференция, посвященная тактике ведения пациентов с онкогематологическими заболевани ями в ургентных клинических ситуациях.На конференции с докладами выступили не только ведущие российские онкологи и гематологи, но и врачи других специальностей (по поддерживающей терапии, инструментальной диагностике, анестезиологи-реаниматологи, акушеры-гинекологи, патоморфологи).Были освещены самые актуальные вопросы диагностики и лечения пациентов в тех случаях, когда незамедлительная правильно выбранная тактика может способствовать благоприятному прогнозу.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89820768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-14DOI: 10.17650/1818-8346-2022-17-2-134-140
S. Ignatiev, A. Lyanguzov, E. Fokina, N. Zorina, K. Vorobiev
{"title":"Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases","authors":"S. Ignatiev, A. Lyanguzov, E. Fokina, N. Zorina, K. Vorobiev","doi":"10.17650/1818-8346-2022-17-2-134-140","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-2-134-140","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79823152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-14DOI: 10.17650/1818-8346-2022-17-2-151-153
A. Editorial
.
．
{"title":"Experts Council Resolution on topical issues in the treatment of patients with idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) and thrombopoietin receptor agonist (avatrombopag)","authors":"A. Editorial","doi":"10.17650/1818-8346-2022-17-2-151-153","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-2-151-153","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79780112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-14DOI: 10.17650/1818-8346-2022-17-2-121-133
A. Veselov, N. Klimko
{"title":"Intravenous posaconazole: key features of clinical pharmacology and practical applications","authors":"A. Veselov, N. Klimko","doi":"10.17650/1818-8346-2022-17-2-121-133","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-2-121-133","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"102 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75916948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-14DOI: 10.17650/1818-8346-2022-17-2-141-150
S. Semochkin, M. Solovyev, L. Mendeleeva
{"title":"Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma","authors":"S. Semochkin, M. Solovyev, L. Mendeleeva","doi":"10.17650/1818-8346-2022-17-2-141-150","DOIUrl":"https://doi.org/10.17650/1818-8346-2022-17-2-141-150","url":null,"abstract":"","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79227659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：